EIR Biopharma

EIR Biopharma, founded in 2019 and based in San Diego, is pioneering a novel therapeutic approach centered on modulating the Ephrin receptor, a key regulator of cellular guidance, survival, and angiogenesis. Its lead asset, EIR-1003, is a small molecule antagonist in preclinical development for glaucoma and other ocular diseases, with a secondary program, EIR-0205, for Stargardt disease. The company leverages partnerships with top academic institutions and is led by a team with extensive biopharma experience, aiming to build a pipeline-in-a-mechanism platform that extends beyond ophthalmology into major disease areas with high unmet need.

Proprietary platform for targeted modulation of Ephrin receptors (EphA and EphB), membrane-bound proteins that regulate axonal guidance, angiogenesis, cell survival, and inflammation. The platform aims to correct dysregulated signaling using small molecule antagonists to provide neuroprotection and anti-angiogenic effects.

In ophthalmology, EIR faces intense competition from large pharma and biotechs pursuing diverse mechanisms for glaucoma (e.g., neurotrophic factors, Rho kinase inhibitors) and dry AMD (complement inhibitors, etc.). Its niche is as a pioneer in Ephrin receptor modulation, but it is far behind later-stage clinical assets. Its platform approach may differentiate it if successfully validated.